Nouscom

Nouscom's proprietary immmunotherapy platforms utilize a portfolio of uniquely engineered viral vectors of long strings of tumor neoantigens and comprise a powerful toolkit for the induction of broad and potent anti-tumor T cell responses. The Company's deep knowledge of vaccine manufacturing, and the platform’s capacity to reliably encode unprecedented numbers of neoantigens is combined with proprietary approaches to neoantigen identification.

Nouscom's mission is to generate safe, innovative, and potent next-generation cancer immunotherapies that selectively eliminate tumor cells. Their published pre-clinical and clinical data indicate that the approach is able to induce strong immune responses with potential to expand the applicability and efficacy of existing immunotherapies while delivering high levels of safety and tolerability.